Abstract
No public abstract is available from the verified source records.
Yahui Fu, Zichen Guo, Yongqi Lv, Changgang Sun, Jing Zhuang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel
10.1038/s41568-023-00660-9 · 2024
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression
10.1038/s41563-020-00849-5 · 2021
Matrix stiffening facilitates the collective invasion of breast cancer through the periostin-integrin mechanotransduction pathway
10.1016/j.matbio.2023.05.006 · 2023
Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor
10.1016/j.cell.2024.04.023 · 2024
Probing the physical hallmarks of cancer
10.1038/s41592-024-02564-4 · 2025
Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning
10.1016/j.celrep.2021.109293 · 2021
Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer
10.1038/s41551-020-00657-x · 2021
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
10.1158/2326-6066.cir-21-0094 · 2021
Local soft niches in mechanically heterogeneous primary tumors promote brain metastasis via mechanotransduction-mediated HDAC3 activity
10.1126/sciadv.adq2881 · 2025
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
10.1038/s41392-023-01480-x · 2023
Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma
10.1002/adma.202501526 · 2025
Mena regulates nesprin-2 to control actin-nuclear lamina associations, trans-nuclear membrane signalling and gene expression
10.1038/s41467-023-37021-x · 2023
High matrix stiffness triggers the YAP-OPA1-TET1/3 loop to drive chemoresistance via enhanced nuclear-mitochondrial communication
10.1016/j.isci.2025.113996 · 2025
KIF5A upregulation by FAK-mediated downregulation of epigenetic modifiers promotes mitochondrial dynamics in neuronal differentiation
10.1002/1873-3468.70177 · 2026
Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression
10.1038/s41392-022-01221-6 · 2023
Smoke-induced SAV1 Gene Promoter Hypermethylation Disrupts YAP Negative Feedback and Promotes Malignant Progression of Non-small Cell Lung Cancer
10.7150/ijbs.73428 · 2022
Histone H1.0 couples cellular mechanical behaviors to chromatin structure
10.1038/s44161-024-00460-w · 2024
Linking cell mechanical memory and cancer metastasis
10.1038/s41568-023-00656-5 · 2024
Compressive stress-driven Piezo1 activation and Rho-ROCK mechanotransduction promote tumor progression via epigenetic mechanical memory
10.1126/sciadv.aeb1271 · 2026
Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids
10.1038/s41563-024-01908-x · 2024
Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets
10.1038/s41698-024-00529-6 · 2024
Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis
10.1038/s41388-024-03144-8 · 2024
Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity
10.1021/acs.jmedchem.4c02183 · 2024
Focal Adhesion Kinase Intersects With the BRD4-MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer
10.1002/cam4.71227 · 2025
Biophysics in tumor growth and progression: from single mechano-sensitive molecules to mechanomedicine
10.1038/s41388-023-02844-x · 2023
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
10.1038/s41392-023-01501-9 · 2023
Matrix-induced nuclear remodeling and mechano-therapeutics
10.1016/j.celrep.2025.116176 · 2025
Mechanical force application to the nucleus regulates nucleocytoplasmic transport
10.1038/s41556-022-00927-7 · 2022
Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma
10.1002/cac2.12364 · 2022
Capillary constrictions prime cancer cell tumorigenicity through PIEZO1
10.1038/s41467-025-63374-6 · 2025
An Agrin-YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung Tumorigenesis
2025
Dissecting cell membrane tension dynamics and its effect on Piezo1-mediated cellular mechanosensitivity using force-controlled nanopipettes
10.1038/s41592-024-02277-8 · 2024
Ligand binding initiates single-molecule integrin conformational activation
10.1016/j.cell.2024.04.049 · 2024
Force-FAK signaling coupling at individual focal adhesions coordinates mechanosensing and microtissue repair
10.1038/s41467-021-22602-5 · 2021
Force transmission by retrograde actin flow-induced dynamic molecular stretching of Talin
10.1038/s41467-023-44018-z · 2023
Stretching single talin rod molecules activates vinculin binding
10.1126/science.1162912 · 2009
Alternative molecular mechanisms for force transmission at adherens junctions via β-catenin-vinculin interaction
10.1038/s41467-024-49850-5 · 2024
Matrix stiffness induces epithelial-to-mesenchymal transition via Piezo1-regulated calcium flux in prostate cancer cells
10.1016/j.isci.2023.106275 · 2023
Cell-extracellular matrix mechanotransduction in 3D
10.1038/s41580-023-00583-1 · 2023
Nuclear deformation and dynamics of migrating cells in 3D confinement reveal adaptation of pulling and pushing forces
10.1126/sciadv.adm9195 · 2024
Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy
10.1038/s41565-022-01122-3 · doi-reference
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
10.1038/s41698-025-00876-y · doi-reference
A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development
10.1186/s13046-025-03328-4 · doi-reference
Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology
10.1186/s12967-025-06593-1 · doi-reference
Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment
10.1186/s13059-024-03435-z · doi-reference
Identification of matrix stiffness-related molecular subtypes in HCC via integrating multi-omics analysis and machine learning algorithms
10.1186/s12967-025-06733-7 · doi-reference
Gastrointestinal pan-cancer landscape of tumor matrix heterogeneity identifies biologically distinct matrix stiffness subtypes predicting prognosis and chemotherapy efficacy
10.1016/j.csbj.2023.04.016 · doi-reference
3D In Vitro Models for Investigating the Role of Stiffness in Cancer Invasion
10.1021/acsbiomaterials.0c01530 · doi-reference
Lung adenocarcinoma cells respond differently to mechanical stress in 3D versus 2D environments
10.1038/s42003-025-09179-1 · doi-reference
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
10.1016/j.apsb.2023.02.001 · doi-reference
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
10.1038/s41523-017-0053-3 · doi-reference
Engineering approaches for understanding mechanical memory in cancer metastasis
10.1063/5.0194539 · doi-reference
Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis
10.1038/s41467-025-56299-7 · doi-reference
Structure, function and assembly of nuclear pore complexes
10.1038/s41580-025-00881-w · doi-reference
Biomechanical networks of the pre-metastatic niche: Decoding biophysical determinants of tumor metastatic organotropism
10.1016/j.canlet.2025.218102 · doi-reference
Mechanotransduction and epigenetic modulations of chromatin: Role of mechanical signals in gene regulation
10.1002/jcb.30531 · doi-reference
Fluid shear stress activates a targetable mechano-metastatic cascade to promote medulloblastoma metastasis
10.1038/s41551-025-01487-5 · doi-reference
Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells
10.1016/j.actbio.2025.12.020 · doi-reference
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles
10.1016/j.ejmech.2021.113569 · doi-reference
The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo
10.1016/j.bioorg.2022.106328 · doi-reference
YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma
10.1111/pcmr.70036 · doi-reference
Sequential YAP1/FOSL1 silencing and epigenetic therapy to overcome stromal barriers in pancreatic cancer
10.1016/j.ijpharm.2025.126155 · doi-reference
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer
10.1016/j.ebiom.2021.103457 · doi-reference
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma
10.1016/j.canlet.2024.217261 · doi-reference
Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1
10.7150/thno.85437 · doi-reference
A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic Screen
10.1158/1535-7163.mct-19-0330 · doi-reference
High-effect synergy from dual HDAC6 and YAP-TEAD inhibition in ovarian clear cell carcinoma
10.1186/s12935-026-04204-7 · doi-reference
Getting the right combination to break the epigenetic code
10.1038/s41571-024-00972-1 · doi-reference
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
10.1158/1078-0432.ccr-22-0175 · doi-reference
Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial
10.1038/s41591-024-03060-0 · doi-reference
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
10.1016/s1470-2045(20)30451-4 · doi-reference
Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
10.1200/jco-24-02612 · doi-reference
Advances in targeting histone deacetylase for treatment of solid tumors
10.1186/s13045-024-01551-8 · doi-reference
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
10.1136/jitc-2024-010294 · doi-reference
Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
10.1038/s42003-022-03509-3 · doi-reference
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
10.1158/1078-0432.ccr-20-3946 · doi-reference
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
10.1136/jitc-2022-004495 · doi-reference
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
10.1136/jitc-2020-000883 · doi-reference
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
10.1158/1078-0432.ccr-22-3642 · doi-reference
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
10.1186/s13148-022-01367-8 · doi-reference